Drugs / TTX-030
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04306900 | Mar 2020 → Nov 2022 | cancer | Trishula Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03884556 | Apr 2019 → Nov 2022 | cancer, lymphoma | Trishula Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06119217 | Mar 2024 → Nov 2025 | malignant pancreatic neoplasm | Trishula Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTX-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03884556 ↗ |
| Action | Inhibit | “inhibits CD39 enzymatic activity” NCT03884556 ↗ |